Real world evidence of the use of metamizole (dipyrone) by the Brazilian population. A retrospective cohort with over 380,000 patients.

Henry Sznejder Caroline Amand Andrew Stewart Ricardo Salazar Wanessa Alessandra Ruiz Scala

Published in: Einstein (Sao Paulo, Brazil) (2022)

Real world evidence to evaluate Brazilian patients' therapeutic options is unusual and yet to be more explored using digital tools enabling better data registration. The present study confirmed that metamizole is widely used as a non-anti-inflammatory drug, and also showed the management of pain and fever as the most frequent indications in all age groups studied.Registry in Clinical Trials Database: REBEC Database: 10507.

Keyphrases

end stage renal disease
clinical trial
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
anti inflammatory
randomized controlled trial
chronic pain
patient reported outcomes
adverse drug
neuropathic pain
patient reported
double blind